China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing agreement with Duality Biotherapeutics, a novel modality drug developer with operations in both the United States and China. This strategic partnership aims to leverage Duality’s expertise in developing innovative therapies.
Financial Terms and Milestones
According to the agreement, Duality Biologics will receive an upfront payment and is eligible for additional payments should BeiGene exercise its option. The total potential value of the agreement, including development, regulatory, and commercial milestones, could reach up to USD 1.3 billion, plus tiered royalties on future sales. This significant investment underscores the confidence in Duality’s drug development capabilities.
Global Rights and Research Responsibilities
Upon exercising its option, BeiGene will secure global clinical, manufacturing, and commercial rights, while Duality Biologics will be responsible for conducting all research activities through IND-enabling studies and supporting future IND filings by BeiGene. This collaboration aligns with BeiGene’s strategy to expand its global footprint in the biopharmaceutical industry.
Duality’s ADC Capabilities Recognized Again
Duality’s ADC (Antibody-Drug Conjugate) capabilities have been recognized with this second major deal of the year. In April, the company handed over rights to two ADCs to Germany-based BioNTech in a deal worth up to USD 1.67 billion. This latest agreement with BeiGene further solidifies Duality’s position as a key player in the development of novel drug modalities.-Fineline Info & Tech
